Evercore ISI raised the firm’s price target on Labcorp (LH) to $300 from $280 and keeps an Outperform rating on the shares. The firm made several price target adjustments and additions to the firm’s Tactical call lists as part of the firm’s healthcare technology and distribution preview for Q1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp Sets Date for First-Quarter 2026 Results
- Labcorp Holdings Secures New $750 Million Term Loan
- Labcorp, Illumina expand collaboration to broaden access to oncology testing
- Labcorp price target raised to $300 from $270 at Piper Sandler
- Labcorp collaborates with PathAI to deploy FDA-cleared pathology platform